跳至主要内容
临床试验/IRCT20200918048751N1
IRCT20200918048751N1招募中3 期

The effectiveness of memantine in improving cognitive deficits, quality of life and reducing the negative symptoms of schizophrenia patients

Zanjan University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 50 years(—)
性别
All

入选标准

  • Having diagnostic criteria (DSM-5) for patients with schizophrenia and at least two years after diagnosis
  • Age 18 to 50 years
  • Receive a fixed dose of antipsychotic for at least 8 weeks and for 4 weeks before enrollment
  • Continue treatment with at least one antipsychotic drug during the study

排除标准

  • Outstanding neurological or organic disease in clinical and laboratory studies
  • Existence of another axis-based diagnosis (DSM-5)
  • Coexistence with mental retardation
  • Drug addiction or abuse (except nicotine and caffeine)
  • Inability to communicate
  • High risk of suicide
  • Receive ECT in the last two weeks
  • History of memantine sensitivity
  • Having kidney disease
  • Pregnancy and lactation
  • Do not use safe contraception in women

研究者

相似试验